Sarcopenia: Fighting Age-Related Muscle Loss

Sarcopenia is unusual among longevity topics: it has an agreed clinical definition, validated diagnostic cut-points, and an intervention supported by more than a hundred randomized trials. It also has no approved drug. That combination is worth sitting with, because it means the boring answer is the evidence-backed one.

What actually counts as sarcopenia

The 2019 European consensus (EWGSOP2) restructured the definition around strength rather than mass. Low muscle strength alone establishes probable sarcopenia; adding low muscle quantity or quality confirms it; adding poor physical performance makes it severe. The Asian Working Group for Sarcopenia reached a parallel consensus with slightly different thresholds — the cut-points are population-calibrated, not universal constants.

Measure	EWGSOP2 (Europe)	AWGS 2019 (Asia)
Low grip strength	<27 kg (men) / <16 kg (women)	<28 kg (men) / <18 kg (women)
Low muscle mass (ASM/height², DXA)	<7.0 / <5.5 kg/m²	<7.0 / <5.4 kg/m²
5-time chair stand	>15 s	≥12 s
Slow gait speed	≤0.8 m/s	<1.0 m/s
SPPB	≤8	≤9

AWGS also added a “possible sarcopenia” category — low strength or low performance — explicitly so primary care can start lifestyle interventions before a full diagnostic workup.

Resistance training: the strongest evidence in the field

A Cochrane review pooling 121 randomized trials in 6,700 older adults found progressive resistance training produced a large gain in muscle strength (SMD 0.84, 95% CI 0.67 to 1.00) and increased gait speed by 0.08 m/s (95% CI 0.04 to 0.12). Serious adverse events were rare and none were attributed to the training itself.

The same review found a moderate-to-large improvement in chair-rise time (SMD −0.94, 95% CI −1.49 to −0.38, 11 trials) and a small but statistically significant improvement in overall physical ability (SMD 0.14, 95% CI 0.05 to 0.22, 33 trials, 2,172 participants). Most protocols trained two to three times per week at high intensity.

That last number deserves honesty rather than enthusiasm. Strength gains are large; translation into complex everyday tasks is modest. Training reliably makes older people stronger and slightly faster on their feet — it is not a wholesale reversal of functional decline.

Protein: necessary, but a smaller lever than advertised

The PROT-AGE position paper recommends at least 1.0–1.2 g of protein per kg of body weight per day for people over 65, ≥1.2 g/kg/day for those who are active, and 1.2–1.5 g/kg/day for those with acute or chronic disease — alongside both endurance and resistance exercise.

What extra protein adds on top of training is smaller than the supplement aisle implies. A 2022 meta-analysis of 74 randomized trials (2,665 participants for the lean-mass analysis) found higher protein plus resistance training produced a small additional gain in lean body mass — SMD 0.22, roughly 0.5–0.7 kg. That effect was significant in adults under 65 and marginal and non-significant in those 65 and over. Below 1.2 g/kg/day there was no effect at all, handgrip strength showed no significant benefit, and the six trials of protein without resistance exercise were non-significant with low certainty.

Hit the intake threshold so protein is not the limiting factor, then stop optimising it and go train.

What about drugs and peptides?

No pharmacological therapy is approved for sarcopenia in the United States or Europe. A 2025 review of trial endpoints and regulatory issues notes that regulatory bodies “seem to be unwilling to consider sarcopenia as an indication for drug therapy,” and that approval would require clinically meaningful changes in patient-reported outcomes, physical function, or morbidity and mortality — measured with validated tools such as the SPPB, gait speed or the 6-minute walk. Investigational compounds exist; none has cleared that bar, and no peptide has evidence remotely comparable to the training literature.

The takeaway

Sarcopenia is the rare longevity target where the evidence is strong and the instruction is dull. Progressive resistance training two to three times a week substantially improves strength and measurably improves gait speed in older adults, across 121 trials, with rare adverse events. Adequate protein — 1.0–1.2 g/kg/day, more if you train or are unwell — is the necessary substrate, but adding protein without adding load buys very little. There is no approved drug. See also strength training for longevity and grip strength as a longevity marker. This article is educational and not medical advice.

Sources

• Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2, Age and Ageing, 2019)
• Asian Working Group for Sarcopenia: 2019 Consensus Update (JAMDA, 2020)
• Progressive resistance strength training for improving physical function in older adults (Cochrane Database of Systematic Reviews, 2009)
• Evidence-based recommendations for optimal dietary protein intake in older people (PROT-AGE, JAMDA, 2013)
• Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults (Journal of Cachexia, Sarcopenia and Muscle, 2022)
• Sarcopenia in ageing and chronic illness: trial endpoints and regulatory issues (Journal of Cachexia, Sarcopenia and Muscle, 2025)

This is sample content created during site scaffolding. Sources have been attached but each claim still needs verification against them before launch.